IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
- Conditions
- Pancreatic Ductal AdenocarcinomaColorectal CancerSolid TumorMelanomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 220
- Registration Number
- NCT06305247
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute - California, Los Angeles, California, United States
🇺🇸UC San Diego Health System - La Jolla, San Diego, California, United States
🇺🇸Yale Cancer Center - New Heaven, New Haven, Connecticut, United States
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
- Conditions
- Pregnancy Related
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT06258902
- Locations
- 🇺🇸
Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina, United States
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
- Conditions
- Gastro-enteropancreatic Neuroendocrine TumorAcromegaly
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT06253897
- Locations
- 🇺🇸
Pearl IRB, Indianapolis, Indiana, United States
CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity
- Conditions
- Upper Limb Injury
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 113
- Registration Number
- NCT06245772
- Locations
- 🇫🇷
CH Bagnères, Bagnères-de-Bigorre, France
🇫🇷CH Bar le Duc, Bar-le-Duc, France
🇫🇷Besançon - CHU/CRRF de Bréguille/Salin les bains, Besançon, France
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Fibrodysplasia Ossificans Progressiva
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 70
- Registration Number
- NCT06089616
- Locations
- 🇨🇦
Edmonton Clinic Health Academy (ECHA)- University of Alberta, Edmonton, Canada
🇨🇦Bone Research and Education Centre, Oakville, Canada
🇨🇦University Health Network (UHN) - Toronto General, Toronto, Canada
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
- Conditions
- Spasticity as Sequela of Stroke
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1051
- Registration Number
- NCT06055725
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol (HUGTP), Badalona, Spain
🇪🇸Hospital Universitario Miguel Servet de Zaragoza, Zaragoza, Spain
🇬🇧Kings College Hospital NHS Foundation Trust, London, United Kingdom
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
- Conditions
- Episodic Migraine
- Interventions
- Other: Placebo
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 714
- Registration Number
- NCT06047457
- Locations
- 🇺🇸
Hope Clinical Research, LLC, Canoga Park, California, United States
🇺🇸Axiom Research LLC, Colton, California, United States
🇺🇸Alliance Clinical San Diego (Acclaim Clinical Research), San Diego, California, United States
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
- Conditions
- Chronic Migraine
- Interventions
- Other: Placebo
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 720
- Registration Number
- NCT06047444
- Locations
- 🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸CCT Research, Phoenix, Arizona, United States
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Other: Matched 80 mg placebo
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 276
- Registration Number
- NCT06016842
- Locations
- 🇺🇸
Arizona Liver Health, Tucson, Arizona, United States
🇺🇸Arkansas Diagnostic Center, PA, Little Rock, Arkansas, United States
🇺🇸Southern California Research Center, Coronado, California, United States
A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 191
- Registration Number
- NCT05922579
- Locations
- 🇦🇺
CAPPRE, Sidney, Australia